INTRODUCTION {#S1}
============

Innate lymphoid cells (ILCs) are recently identified innate immune cells that serve important roles in lymphoid tissue formation, repair of damaged tissues, and homeostasis, as well as in immunity against infectious microorganisms ([@R62]; [@R16]; [@R34]). ILCs are categorized into three groups based on their unique expression of transcription factors, surface markers, and the production of effector cytokines ([@R63]; [@R69]). ILC1s are characterized by interferon gamma (IFNγ) production and ILC2s by interleukin-5 (IL-5) and IL-13, while ILC3s are characterized by IL-17 and IL-22. Natural killer (NK) cells are considered a cytotoxic subset of ILC1s ([@R63]). Distinct from adaptive immune cells such as T cells and B cells, ILCs do not possess antigen-specific receptors ([@R62]). ILCs appear to be tissue resident cells and are maintained mostly by selfrenewal in homeostatic settings ([@R21]; [@R47]). We recently found that cardiac ILCs are also a resident population that are type 2-skewed in both human and mouse hearts ([@R5]). However, what roles cardiac ILCs play in inflammation are poorly understood.

ILC2s are found in many organs at steady state, including lung and mucosal tissues, and can be activated by IL-33, IL-25, and thymic stromal lymphopoietin (TSLP) ([@R31]; [@R34]; [@R46]; [@R49]; [@R52]; [@R32]). After activation, ILC2s produce T helper 2 cell (Th2)-associated cytokines, such as IL-5 and IL-13 ([@R46]; [@R49]; [@R52]). These Th2 cytokines have been implicated in eosinophil proliferation, recruitment, and homeostasis ([@R50]; [@R52]). The role of ILC2s in infection and inflammation has been investigated mostly in mucosa-associated tissues and skin. ILC2s are beneficial in promoting immunity to parasite infection with *Nippostrongylus brasiliensis* ([@R46]; [@R49]). In this helminth infection model, IL-25 and IL-33 were shown to be critical for ILC2 activation, and IL-13 produced by ILC2s mediated worm expulsion ([@R49]). In contrast to the protective immunity provided by ILC2s, IL-33-activated ILC2s are also involved in the pathogenesis of asthma and atopic dermatitis promoting inflammation in the lungs and skin, respectively ([@R24]; [@R54]; [@R27]). Moreover, the enrichment of ILC2s was reported in biopsy samples from patients with eosinophilic esophagitis and atopic dermatitis ([@R14]; [@R54]).

IL-33 is a cytokine of the IL-1 family and functions as an alarmin, which is released from cells upon tissue damage or cellular stress ([@R57]; [@R7]; [@R44]). IL-33 is usually expressed and released from epithelial and endothelial cells, and it is also shown to be expressed in stromal cells such as fibroblastic reticular cells in the lymph nodes ([@R48]; [@R51]). The profiling of IL-33 mRNA expression in mouse tissues revealed that the heart had a relatively low expression of IL-33 compared to mucosal and barrier-related tissues such as lung and skin ([@R57]). The role of IL-33 in the heart has been shown to be beneficial in some mouse models of cardiovascular diseases. IL-33 treatment reduced cardiac hypertrophy in a mouse model of transverse aortic constriction and improved cardiac function and survival in a myocardial infarction mouse model ([@R55]; [@R8]; [@R59]). However, the administration of IL-33 induced pericarditis in mice with an increased proportion of eosinophils in the heart of naive and coxsackievirus B3 (CVB3)-infected mice, demonstrating that IL-33 can also play a pathogenic role in the heart ([@R2]). IL-33 has been shown to activate and expand ILC2s ([@R46]; [@R49]; [@R68]; [@R31]). This suggests that the described pathogenic effect of IL-33 in the heart could be mediated by the activation of ILC2s.

Here, we show that ILCs in the heart play a pathogenic role in promoting cardiac inflammation. Cardiac ILC2s activated by IL-33 caused eosinophilic pericarditis. The IL-33-ST2 signaling axis was important for the expansion of cardiac ILC2s and induction of pericarditis. We identified that ILCs, not T cells and B cells, were required for IL-33-induced pericarditis. *Rag2*^−/−^*Il2rg*^−/−^ mice deficient in lymphocytes, including ILCs, were protected from pericarditis; however, ILC2 transfer to the heart restored the susceptibility of *Rag2*^−/−^*Il2rg*^−/−^ mice to eosinophil infiltration to the heart. We also found that ILC2s induced cardiac fibroblasts to produce eotaxin-1 to direct eosinophil trafficking to the heart. Moreover, we discovered that eosinophils resided in the mediastinal cavity of naive mice, which serves as a reservoir of eosinophils. We documented the recruitment of eosinophils from the mediastinal cavity, which could be an alternate route in addition to the conventional vascular trafficking of eosinophils to the heart. Finally, we showed that, in humans, ILCs are found more frequently in pericardial fluid from pericarditis patients compared to individuals without cardiac diseases and patients with other types of cardiac diseases.

RESULTS {#S2}
=======

Number of ILC2s Increases in the Heart after IL-33 Treatment {#S3}
------------------------------------------------------------

ILC2s express the IL-33 receptor, which is also known as ST2, and become activated and proliferative upon IL-33 stimulation ([@R63]; [@R69]; [@R34]). To determine whether IL-33 induces an increase in ILC2s in the heart *in vivo*, we used the IL-33-induced pericarditis model in which mice are treated with IL-33 intraperitoneally every other day for 9 days ([@R2]). IL-33-treated mice developed severe pericarditis compared to PBS-treated mice ([Figure 1A](#F1){ref-type="fig"}). The inflammation mostly affected the pericardium; however, in some cases, the adjacent myocardium was also inflamed ([Figure 1A](#F1){ref-type="fig"}). We also found that IL-33-treated mice showed an increased infiltration of immune cells in other organs including esophagus and lungs ([Figures S1A](#SD1){ref-type="supplementary-material"} and [S1B](#SD1){ref-type="supplementary-material"}). We assessed cardiac function of the heart by performing M-mode and Doppler echocardiography. A typical pattern of ventricular dilation was present in IL-33-treated mice examined by M-mode echocardiography ([Figure 1B](#F1){ref-type="fig"}). IL-33 treatment resulted in reduced ejection fraction (EF) and fractional shortening (FS) ([Figures 1C](#F1){ref-type="fig"} and [1D](#F1){ref-type="fig"}). Other parameters were comparable; however, the left ventricular posterior wall at end-systole was thinner in IL-33-treated mice ([Figures S1C](#SD1){ref-type="supplementary-material"}-[S1E](#SD1){ref-type="supplementary-material"}). In addition, IL-33-treated mice showed significantly longer isovolumetric relaxation time (IVRT), an indicator of diastolic function, and higher myocardial performance index (MPI), a useful predictor of global cardiac function, than PBS-treated mice ([Figures 1E](#F1){ref-type="fig"} and [1F](#F1){ref-type="fig"}). Prolonged IVRT indicates poor myocardial relaxation related to pericardial constriction, and high MPI represents both systolic and diastolic dysfunction. These data suggest that pericarditis induced by IL-33 resulted in abnormal cardiac function. We analyzed the number of heart-infiltrating CD45^+^ leukocytes by flow cytometry and found that it was significantly increased in IL-33-treated mice compared to PBS-treated mice, confirming that inflammation occurred in the heart as a result of IL-33 treatment ([Figure 1G](#F1){ref-type="fig"}). We identified ILC2s in the heart as CD45^+^Lin^−^CD90^+^KLRG1^+^ST2^+^ ([Figure S2A](#SD1){ref-type="supplementary-material"}). Lin included CD3ε, TCRβ, CD19, B220, CD11b, CD11c, Gr-1, Ter119, FcεRIα, and NKp46, and was used to exclude cell populations that may contaminate ILC2s. Both the number and frequency of ILC2s in the heart were dramatically increased upon IL-33 treatment compared to PBS treatment ([Figures 1H](#F1){ref-type="fig"} and [S2B](#SD1){ref-type="supplementary-material"}). We also analyzed other heart-infiltrating immune cells and found that the number and frequency of CD11b^+^SiglecF^+^ eosinophils were increased in the heart of IL-33-treated mice and that they were the most abundant cells among heart infiltrates ([Figures 1I](#F1){ref-type="fig"} and [S2C](#SD1){ref-type="supplementary-material"}). The number and frequency of other immune cells known to express ST2, including FcεRIα^+^CD117(c-Kit)^+^ mast cells, remained unchanged ([Figure 1J](#F1){ref-type="fig"}). To visualize the distribution of ILC2s and eosinophils in pericarditis, we used a tissue-clearing technique with the right ventricle of the heart from mice treated with IL-33. We found that ILC2s and eosinophils were located in the right ventricle near the pericardium and in the atria, which is consistent with the finding that inflammation was mostly observed in the right ventricle in the histological analysis ([Figure 1K](#F1){ref-type="fig"}; [Video S1](#SD3){ref-type="supplementary-material"}). In addition, the number of CD11b^+^Ly6G^+^ neutrophils in the heart was decreased in IL-33-treated mice; however, we did not find significant changes in numbers of macrophages, monocytes, T cells, B cells, and NK cells ([Figures S2D](#SD1){ref-type="supplementary-material"}-[S1I](#SD1){ref-type="supplementary-material"}). We found that the level of anti-myosin immunoglobulin M (IgM) antibody in serum was significantly higher in IL-33-treated mice than in PBS-treated mice on day 9 ([Figure S2J](#SD1){ref-type="supplementary-material"}). Anti-myosin IgG and IgE were found at a negligible level in the sera of both PBS- and IL-33-treated mice (data not shown). These results indicate that IL-33-induced pericarditis is characterized by impaired cardiac function and an increased number of ILC2s and eosinophilsin the heart.

IL-33-ST2 Signaling Pathway Is Critical for ILC Accumulation in the Heart and the Development of Pericarditis {#S4}
-------------------------------------------------------------------------------------------------------------

To determine whether the development of pericarditis is dependent on the IL-33-ST2 signaling pathway, ST2^−/−^ (*Il1rl1*^−/−^) mice were treated with IL-33. ST2^−/−^ mice were completely protected from the development of IL-33-induced pericarditis, whereas wild-type (WT) mice developed pericarditis ([Figures 2A](#F2){ref-type="fig"} and [2B](#F2){ref-type="fig"}). The number of total leukocyte infiltrates was significantly reduced in the heart of ST2^−/−^ mice compared to WT mice ([Figure 2C](#F2){ref-type="fig"}). To further confirm the dependency of ILC2 accumulation in the heart on IL-33 signaling, we analyzed the Lin^−^CD90^+^KLRG1^+^ ILC population in the heart of ST2^−/−^ mice after IL-33 treatment. We found that ILCs were significantly reduced in the heart of ST2^−/−^ mice compared to WT mice ([Figures 2D](#F2){ref-type="fig"} and [2E](#F2){ref-type="fig"}). The number of eosinophils was also decreased in the heart of ST2^−/−^ mice ([Figure 2F](#F2){ref-type="fig"}). This demonstrates that IL-33 signaling through ST2 is important for the development of pericarditis, and the IL-33-ST2 signaling axis is required for ILC2 accumulation in the heart. Next, we assessed whether exogenous IL-33 treatment is involved in a positive feedback loop that results in increased endogenous expression of IL-33. IL-33^cit/+^ reporter mice treated with IL-33 showed a higher expression of IL-33 compared to mice treated with PBS, which indicates the presence of a positive feedback loop of IL-33 expression ([Figures 2G](#F2){ref-type="fig"} and [S3A](#SD1){ref-type="supplementary-material"}). In addition, the number of IL-33-expressing cells was increased after IL-33 treatment ([Figure 2H](#F2){ref-type="fig"}). Most of the IL-33-expressing cells were CD45^−^CD31^−^ stromal cells, and among them, Sca1^+^ fibroblasts were the major IL-33-expressing cells in the heart. These IL-33-expressing cardiac fibroblasts were increased in number after IL-33 treatment, suggesting that cardiac fibroblasts have a capacity to produce IL-33 in both the naive state and during cardiac inflammation ([Figures 2I](#F2){ref-type="fig"} and [2J](#F2){ref-type="fig"}). Sca1^+^ cardiac fibroblasts also expressed platelet-derived growth factor receptor α (PDGFRα), a commonly used cardiac fibroblast marker ([Figure 2K](#F2){ref-type="fig"}). Moreover, we found that IL-33 was spatially expressed by cardiac fibroblasts near and in the pericardium ([Figure 2L](#F2){ref-type="fig"}). We found a correlation of IL-33 and ST2 expression in IL-33-induced pericarditis, indicating the existence of a positive feedback loop in which IL-33 induces greater ST2 expression and IL-33 production by fibroblasts ([Figure S3B](#SD1){ref-type="supplementary-material"}). Furthermore, we examined whether endogenous IL-33 is important to induce pericarditis. We found that the number of total CD45^+^ heart-infiltrating leukocytes was reduced in IL-33^−/−^ mice compared to WT mice upon IL-33 treatment ([Figure S3C](#SD1){ref-type="supplementary-material"}). The number of myeloid cells and eosinophils was also decreased in the heart of IL-33^−/−^ mice ([Figures S3D](#SD1){ref-type="supplementary-material"} and [S3E](#SD1){ref-type="supplementary-material"}). The lack of endogenous IL-33 affected the Lin^−^CD90^+^KLRG1^+^ ILC population, which was reduced in the heart of IL-33^−/−^ mice compared to WT mice ([Figure S3F](#SD1){ref-type="supplementary-material"}). These results indicate that endogenous IL-33 is a required component to induce severe pericarditis, which was initiated by exogenous IL-33 administration. These data suggest that IL-33 signaling through ST2 is important for ILC accumulation in the heart and the development of pericarditis.

ILCs Are Required for Development of IL-33-Induced Pericarditis and Sufficient to Rescue ILC-Deficient Mice Susceptibility to Eosinophil Infiltration {#S5}
-----------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether ILCs are required for the induction of pericarditis, we treated WT, *Rag2*^−/−^, and *Rag2*^−/−^*Il2rg*^−/−^ mice with IL-33. While *Rag2*^−/−^ mice deficient in T cells and B cells developed pericarditis comparable to WT mice, *Rag2*^−/−^*Il2rg*^−/−^ mice, which lack all lymphocytes including ILCs, were completely protected from the development of pericarditis ([Figures 3A](#F3){ref-type="fig"} and [3B](#F3){ref-type="fig"}). Thus, adaptive immune response is not necessary for the induction of pericarditis by IL-33. We assessed leukocytes in the heart and found a significantly reduced number of CD45^+^ cells in the heart of *Rag2*^−/−^*Il2rg*^−/−^ mice compared to both WT and *Rag2*^−/−^ mice ([Figure 3C](#F3){ref-type="fig"}). ILC2s were increased in the heart of WT and *Rag2*^−/−^ mice treated with IL-33, whereas ILC2s were not found in the heart of *Rag2*^−/−^*Il2rg*^−/−^ mice ([Figure 3D](#F3){ref-type="fig"}). IL-33-treated *Rag2*^−/−^*Il2rg*^−/−^ mice showed a smaller number of eosinophils, but more neutrophils in the heart than WT and *Rag2*^−/−^ mice ([Figures 3E](#F3){ref-type="fig"} and [S4A](#SD1){ref-type="supplementary-material"}). These data suggest that ILCs are required for the development of pericarditis induced by IL-33, and adaptive immune cells such as T and B cells may not be involved in the pathogenesis of IL-33-induced pericarditis. To confirm that IL-33-induced pericarditis is ILC2-dependent, we investigated the ability of transferred ILC2s to reverse the resistance of *Rag2*^−/−^*Il2rg*^−/−^ mice to pericarditis development. We performed fluorescence-activated cell sorting (FACS) to isolate CD45^+^Lin^−^CD90^+^ KLRG1^+^ST2^+^ ILC2s from the hearts of CD45.1^+^ WT donor mice after IL-33 treatment ([Figure S4B](#SD1){ref-type="supplementary-material"}). Intravenous transfer of ILC2s was not successful, and we were not able to detect any transferred ILC2s in the heart of recipient mice, which is consistent with the resident status of ILCs and their inability to traffic to the heart from the blood, as we showed before ([@R5]). Therefore, we expanded FACS-sorted CD45.1^+^ ILC2s *in vitro* and injected them directly into the myocardium of ILC-deficient CD45.2^+^ *Rag2*^−/−^*Il2rg*^−/−^ recipient mice followed by IL-33 treatment ([Figure S4C](#SD1){ref-type="supplementary-material"}). Recipient mice in a control group were injected with media in the myocardium followed by IL-33 treatment. We were able to detect CD45.1^+^ ILC2s in the hearts of ILC2-transferred CD45.2^+^ *Rag2*^−/−^*Il2rg*^−/−^ mice on day 9, indicating that ILC2s injected into the myocardium remained for the course of the disease ([Figure 3F](#F3){ref-type="fig"}). The number of heart-infiltrating CD45.2^+^ leukocytes was increased in *Rag2*^−/−^*Il2rg*^−/−^ mice injected with ILC2s compared to mice injected with media ([Figure 3G](#F3){ref-type="fig"}). Eosinophils were significantly increased in the hearts of *Rag2*^−/−^*Il2rg*^−/−^ mice injected with ILC2s compared to mice injected with media, providing evidence of a critical role for cardiac ILC2s in eosinophil recruitment to the heart during the development of pericarditis ([Figures 3H](#F3){ref-type="fig"} and [3I](#F3){ref-type="fig"}). To summarize, ILCs, but not T cells and B cells, are required for the development of pericarditis, and the adoptive transfer of cardiac ILC2s directly to the heart is sufficient to rescue *Rag2*^−/−^*Il2rg*^−/−^ mice susceptibility to eosinophilic cardiac inflammation induced by IL-33.

ILC2s Drive Cardiac Fibroblasts to Upregulate CCL11/Eotaxin-1 Gene Expression {#S6}
-----------------------------------------------------------------------------

Eotaxin production is known to induce eosinophil trafficking into organs following a chemoattractant gradient ([@R53]; [@R4]). We previously found that the eotaxin-CCR3 pathway is the main mechanism for eosinophil trafficking to the heart ([@R13]). We found that the expression of *Ccl11*, a gene encoding eotaxin-1, was upregulated in the heart of IL-33-treated mice compared to PBS-treated mice, while the expression of *Ccl24* encoding eotaxin-2 was comparable between groups ([Figures 4A](#F4){ref-type="fig"} and [S5A](#SD1){ref-type="supplementary-material"}). Our previous work showed that cardiac fibroblasts produce a diverse set of cytokines and chemokines in response to different Th environments ([@R9]). Specifically, in a Th2 environment during eosinophilic cardiac inflammation, cardiac fibroblasts are the main source of eotaxin-1 ([@R13]). To investigate whether ILC2s and cardiac fibroblasts cooperate to attract eosinophils to the heart in IL-33-induced pericarditis, we devised a co-culture system in which cardiac fibroblasts are co-cultured with ILC2s separated by 0.4-μm transwells ([Figure 4B](#F4){ref-type="fig"}). This enabled ILC2s to interact with cardiac fibroblasts through soluble factors such as cytokines, but not through direct contact. We found that cardiac fibroblasts significantly upregulated *Ccl11* expression when co-cultured with ILC2s in the presence of IL-33, compared to cardiac fibroblasts cultured without ILC2s in the absence or presence of IL-33 ([Figure 4C](#F4){ref-type="fig"}). *Ccl24* expression by cardiac fibroblasts did not significantly differ ([Figure S5B](#SD1){ref-type="supplementary-material"}). Eotaxin-1 concentration in the cell culture supernatant was also significantly increased in the co-culture condition in which cardiac fibroblasts are cultured with ILC2s in the presence of IL-33 ([Figure 4D](#F4){ref-type="fig"}). To determine whether ILC2s are required for increased eotaxin expression *in vivo*, we examined expression levels of genes related to eosinophil trafficking and ILC2 effector cytokines in the heart of WT, *Rag2*^−/−^, and *Rag2*^−/−^*Il2rg*^−/−^ mice treated with IL-33. We found that the expression of both *Ccl11* and *Ccl24* was significantly decreased in *Rag2*^−/−^*Il2rg*^−/−^ mice compared to WT mice ([Figures 4E](#F4){ref-type="fig"} and [4F](#F4){ref-type="fig"}). The expression levels of *Il5* and *Il13*, encoding ILC2 effector cytokines, were also downregulated in *Rag2*^−/−^*Il2rg*^−/−^ mice ([Figures 4G](#F4){ref-type="fig"} and [4H](#F4){ref-type="fig"}). These data suggest that ILCs may be required for eotaxin expression *in vivo*, possibly in an ILC2 effector cytokines-dependent way. We also examined the spatial expression of eotaxin-1 in the heart and found that eotaxin-1 was highly produced near the pericardium, where pericarditis occurs ([Figure 4I](#F4){ref-type="fig"}). In summary, ILC2s are able to stimulate cardiac fibroblasts to produce eotaxin-1 via soluble factors, suggesting a role for ILC2s and cardiac fibroblasts in the recruitment of eosinophils into the heart.

ILC2-Derived IL-5 Affects the Development of IL-33-Induced Pericarditis {#S7}
-----------------------------------------------------------------------

We assessed cytokine production by cardiac ILC2s on day 9 post-IL-33 treatment using flow cytometry. We found that ILC2s in the heart produced both IL-5 and IL-13 after IL-33 treatment ([Figure 5A](#F5){ref-type="fig"}). Eighty percent of ILC2s found in the heart produced both IL-5 and IL-13 ([Figure 5B](#F5){ref-type="fig"}). To examine the role of IL-5 in the development of pericarditis, we depleted IL-5 in IL-33-treated mice using an anti-IL-5 monoclonal antibody (mAb). We found that mice injected with IL-5-neutralizing mAb showed a trend of less severe pericarditis by histology after IL-33 administration compared to those injected with isotype control ([Figure 5C](#F5){ref-type="fig"}). In addition, we found that the total number of leukocytes in the heart was significantly decreased in anti-IL-5-treated mice compared to isotype-treated controls ([Figure 5D](#F5){ref-type="fig"}). Eosinophils were also significantly reduced in the heart of anti-IL-5-treated mice compared to isotype-treated mice ([Figure 5E](#F5){ref-type="fig"}). However, the number of ILC2s was similar between groups ([Figure 5F](#F5){ref-type="fig"}). These data show that IL-5 produced by ILC2s drives eosinophil infiltration to the heart and contributes to the severity of pericarditis. We also examined whether IL-13 plays a role in pericarditis development. IL-13^−/−^ mice showed pericarditis similar to WT mice ([Figure 5G](#F5){ref-type="fig"}). We found the number of total leukocytes and eosinophils were analogous between WT and IL-13^−/−^ mice ([Figures 5H](#F5){ref-type="fig"} and [5I](#F5){ref-type="fig"}). ILC2s did not differ in number between WT and IL-13^−/−^ mice with pericarditis ([Figure 5J](#F5){ref-type="fig"}). These data suggest that IL-5 derived from ILC2s affects the development of pericarditis and cardiac infiltrating immune cells.

Eosinophils Are Present in the Mediastinal Cavity and Can Migrate to the Heart {#S8}
------------------------------------------------------------------------------

Previously, we found that the eotaxin-CCR3 pathway is critical for eosinophil migration to the heart during eosinophilic myocarditis ([@R13]). We also showed that ILC2s stimulated by IL-33 promote eotaxin-1 production by cardiac fibroblasts ([Figures 4C](#F4){ref-type="fig"} and [4D](#F4){ref-type="fig"}). However, given that IL-33-induced cardiac inflammation has a unique disease pattern affecting predominantly the pericardium and myopericardium, we wanted to explore whether eosinophils could migrate from a non-vascular source such as the mediastinal cavity, a neighboring serosal cavity. In mice, there are pericardial pores between the pericardial, pleural, and mediastinal cavities ([@R19]). We found that eosinophils resided in the mediastinal cavity of naive WT mice at a frequency comparable to that of eosinophils in the heart ([Figures 6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}). To examine whether eosinophils would be present in the mediastinal cavity in higher numbers in hypereosinophilia, we examined eosinophils in the mediastinal cavity of naive IL-5 transgenic (IL-5Tg) mice, which spontaneously develop tissue and blood eosinophilia ([@R36]). In IL-5Tg mice, we found eosinophils at a high frequency in the mediastinal cavity, as well as in the heart and blood ([Figures 6C](#F6){ref-type="fig"} and [6D](#F6){ref-type="fig"}). The frequency of neutrophils in the mediastinal cavity of both WT and IL-5Tg mice was significantly lower compared to the frequency in the blood of these mice, indicating that eosinophils found in the mediastinal cavity were not from blood contamination ([Figures S6A](#SD1){ref-type="supplementary-material"}and [6B](#SD1){ref-type="supplementary-material"}). We found that PBS-treated WT mice had a frequency of eosinophils and neutrophils in the heart, mediastinal cavity, and blood similar to that of naive WT mice ([Figures 6B](#F6){ref-type="fig"}, [S6A](#SD1){ref-type="supplementary-material"}, [S6C](#SD1){ref-type="supplementary-material"}, and [S6E](#SD1){ref-type="supplementary-material"}). Neutrophils in the blood of IL-33-treated WT mice were found to be higher than in the heart and mediastinal cavity, as shown similarly in naive IL-5Tg mice ([Figures S6B](#SD1){ref-type="supplementary-material"} and [S6F](#SD1){ref-type="supplementary-material"}). However, in IL-33-treated mice, eosinophils were present at a higher frequency in the heart and mediastinal cavity than in the blood ([Figure S6D](#SD1){ref-type="supplementary-material"}). To determine whether eosinophils can migrate to the heart from the mediastinal cavity in addition to the vasculature, we transferred the same number of eosinophils either to the mediastinal cavity or intravenously (i.v.) to IL-33-treated ΔdblGATA1 mice lacking eosinophils ([Figure 6E](#F6){ref-type="fig"}). Both mediastinal cavity and i.v. transfers were performed simultaneously to the same animal. The mediastinal cavity transfer was conducted by the direct injection of eosinophils into the mediastinum without an open-chest surgery. Eosinophils injected into the mediastinal cavity and i.v. were labeled with different fluorescent cell-tracking dyes, CellTrace Violet (CTV) and CellTrace Far Red (CTFR), respectively ([Figures 6E](#F6){ref-type="fig"} and [6F](#F6){ref-type="fig"}). Eosinophils transferred to the mediastinal cavity were found to remain mostly in the cavity, confirming that the transfer to the cavity was correctly performed ([Figure S6G](#SD1){ref-type="supplementary-material"}). We found eosinophils transferred through both routes in the heart of ΔdblGATA1 mice deficient in eosinophils ([Figures 6G](#F6){ref-type="fig"} and [6H](#F6){ref-type="fig"}). Eosinophils transferred to the mediastinal cavity were found at a significantly higher frequency in the heart of ΔdblGATA1 mice compared to eosinophils transferred intravenously ([Figures 6H](#F6){ref-type="fig"} and [6I](#F6){ref-type="fig"}). This indicates that eosinophils can migrate from the mediastinal cavity to the heart in addition to traditional vascular routes. Thus, we demonstrated that eosinophils are present in the mediastinal cavity and increased in the cavity of IL-33-treated mice or hypereosinophilic mice. We also showed that eosinophils can migrate to the heart from the neighboring serosal cavities. In addition to direct eosinophil supply from the circulation, the mediastinal cavity seems to serve as an eosinophil reservoir, leading to non-vascular eosinophil trafficking to the heart in the IL-33-induced pericarditis model.

ILCs Are Increased in the Pericardial Fluid of Human Pericarditis {#S9}
-----------------------------------------------------------------

To investigate the pathophysiological relevance of ILCs in human pericarditis, we examined whether ILCs are increased in the pericardial fluid from pericarditis patients. We collected pericardial fluid from patients with diverse heart diseases, including pericarditis, and comprehensively profiled immune cells from the pericardial space using high-dimensional mass cytometry (Cy-TOF). Pericardial fluid samples were obtained from patients with arrhythmogenic right ventricular cardiomyopathy (ARVC), ischemic heart disease (IHD), valve disease, or pericarditis during surgical procedures or pericardiocentesis. Pericardial fluid specimens obtained from the rapid autopsy of deceased patients with no cardiovascular diseases served as a control. Most of the alive single cells that were isolated from the human pericardial fluid were CD45^+^ leukocytes ([Figure 7A](#F7){ref-type="fig"}). To identify ILCs in the pericardial fluid, we excluded myeloid cells and other lymphoid cells such as granulocytes, macrophages, monocytes, dendritic cells, T cells, B cells, and NK cells using cell-specific markers such as CD66b, CD11b, CD68, CD3, CD19, HLA-DR, and CD56 ([Figure 7A](#F7){ref-type="fig"}). ILCs were then defined as CD127^+^ cells ([Figure 7A](#F7){ref-type="fig"}). We found that, whereas ILCs were a rare population in the pericardial fluid of autopsy controls, the frequency of pericardial ILCs was highly increased in patients with pericarditis compared to controls ([Figures 7B](#F7){ref-type="fig"} and [7C](#F7){ref-type="fig"}). Although other cardiac disease groups such as ARVC, IHD, and valve disease showed a slightly increasing trend of pericardial ILCs compared to controls, the frequency of ILCs in pericarditis was significantly higher than that in other cardiac diseases ([Figures 7B](#F7){ref-type="fig"} and [7C](#F7){ref-type="fig"}). Using conventional flow cytometry, we confirmed that Lin^−^CD127^+^ ILCs were increased in the pericardial fluid from pericarditis patients compared to controls ([Figure 7D](#F7){ref-type="fig"}). These findings suggest that ILCs are a specific population that is increased in the pericardium of patients with pericarditis as we observed in the pericarditis mouse model and that the increase in pericardial fluid ILCs is a unique feature in pericarditis, which is differentiated from other cardiac diseases.

DISCUSSION {#S10}
==========

We demonstrated that ILC2s accumulate in the heart following IL-33 treatment in mice using a previously described model of IL-33-induced pericarditis ([@R2]). We report a pathogenic role for ILC2s in the cardiac inflammation, which implies that cardiac ILC2s activated by IL-33 drive eosinophilic pericarditis in collaboration with cardiac fibroblasts. With advanced visualizing tools using the tissue-clearing technique and light sheet microscopy, we revealed that cardiac ILC2s are located in the ventricles near the pericardium where eosinophilic pericarditis is observed after IL-33 treatment, which supports their role in the development of pericarditis. We identified that ILCs are required for the development of IL-33-induced pericarditis. Given that *Rag2*^−/−^ mice develop comparable cardiac inflammation and pathology to WT mice following IL-33 treatment, we excluded adaptive lymphocytes such as T cells and B cells from being drivers of the development of pericarditis. The necessity of ILC2s in the induction of inflammation has been shown in other organs such as allergen-induced lung inflammation models ([@R24]; [@R33]). Papain causes asthma-like symptoms in *Rag1*^−/−^ mice but not in *Rag2*^−/−^*Il2rg*^−/−^ mice, and ILC-deficient *Rag2*^−/−^*Il2rg*^−/−^ mice reconstituted with ILC2s develop airway inflammation ([@R24]). While *Rag2*^−/−^ mice lack T cells and B cells, *Rag2*^−/−^*Il2rg*^−/−^ mice are deficient in ILCs in addition to T cells and B cells. Unlike *Rag2*^−/−^ mice, *Rag2*^−/−^*Il2rg*^−/−^ mice were protected from IL-33-induced pericarditis, demonstrating that ILCs are required for pericarditis development. Our adoptive transfer experiments showed that cardiac ILC2s transferred directly to the heart of pericarditis-resistant *Rag2*^−/−^*Il2rg*^−/−^ mice elicited cardiac eosinophil infiltration. These findings support the notion that ILCs are tissue resident cells even during acute inflammation as described by us in the heart and others in different organs ([@R21]; [@R47]; [@R5]). IL-33-treated mice had increased anti-myosin IgM antibody found in their sera, which suggests a possible pathogenic role for ILCs in myopericarditis. ILC2s isolated from the lungs promoted the production of immunoglobulin including IgM by B1 and B2 cells *in vitro* ([@R15]).

The IL-33-induced pericarditis model allowed us to investigate the pathogenic role of the IL-33-ST2 axis in ILC2 activation during cardiac inflammation. IL-33 mediates its effects through binding to its receptor ST2 as we demonstrated in cardiac ILC2 activation ([@R57]). ST2 is known to be expressed not only on ILC2s but also on Th2 cells, B cells, basophils, eosinophils, dendritic cells, mast cells, and NK T cells ([@R22]). However, using an adoptive transfer experiment, we showed that ILC2s are essential for IL-33-induced cardiac inflammation. It was reported that IL-33 expression increases during cardiac inflammation or after cardiac injury, representing an association between IL-33 and its pathological outcome in cardiac inflammation ([@R8]; [@R56]). ST2 is not only expressed as a membrane-bound form but also produced as a soluble form (soluble ST2 \[sST2\]) that is released into the circulation. sST2 has been proposed as a prognostic marker for chronic and acute heart failure and aortic stenosis ([@R42]; [@R18]; [@R10]; [@R39]). This is consistent with our findings that the IL-33-ST2 axis plays a key pro-inflammatory role in the heart by stimulating cardiac ILC2s under certain conditions related to increased IL-33 production. It should be noted that IL-33 signaling via ST2 could play a beneficial role in different types of heart disease such as pressure overload and myocardial infarction by providing improved cardiac function and survival ([@R55]; [@R59]).

We showed that IL-33 is expressed in naive heart, and its expression is increased in pericarditis, suggesting its pathogenic role in cardiac inflammation. When mice were treated with exogenous IL-33, its endogenous expression was increased in the heart, thus offering evidence for the presence of a positive feedback loop in the heart. Moreover, IL-33-deficient mice developed less severe inflammation with smaller number of infiltrating leukocytes, including eosinophils compared to WT mice after exogenous IL-33 treatment, which indicates the importance of endogenous IL-33 as a component of the positive feedback loop in the development of pericarditis. Thus, the IL-33-induced pericarditis model does not rely solely on exogenous IL-33 administration, but endogenous IL-33 may contribute to an increased IL-33 level in the heart leading to the development of disease. We identified that Sca1^+^ cardiac fibroblasts are major producers of IL-33 in the heart, both in steady state and during pericarditis. We previously found that cardiac fibroblasts are a versatile stromal cell type capable of producing different sets of cytokines and chemokines in response to changes in the microenvironment ([@R9]; [@R13]). The IL-33-expressing cardiac fibroblasts are located near and in the pericardium, supporting the possible involvement of cardiac fibroblasts in ILC2 activation and pericarditis development through their IL-33 expression. Although it has been reported that endothelial cells or cardiomyocytes could be an important source for IL-33, we did not find mouse endothelial cells to be a major producer of IL-33 in the heart ([@R51]; [@R48]; [@R35]; [@R11]). In our model, we found that cardiac fibroblasts are potent IL-33 producers and increase IL-33 production in response to systemic IL-33 administration, suggesting the existence of a feed-forward loop.

ILC2s produce Th2 cytokines such as IL-5 and IL-13 upon activation with IL-33. We were able to show that IL-33-activated ILC2s induce eotaxin-1 (CCL11) production by cardiac fibroblasts. We previously found that cardiac fibroblasts are the major CCL11 producers in eosinophilic myocarditis mouse model, and CCL11 expression is induced in cardiac fibroblasts *in vitro* in response to IL-4 and IL-13 ([@R13]). It has been reported that IL-13 potently induces eotaxin expression in lung epithelial cells, esophagus, and other organs ([@R37]; [@R41]; [@R73]; [@R45]; [@R64]; [@R3]). We found, *in vivo*, that cardiac ILC2s are potent producers of IL-13 upon IL-33 activation. Furthermore, cardiac ILC2s are capable of inducing the production of CCL11 by cardiac fibroblast *in vitro*. The expression of eotaxin and type 2 cytokines in the heart was downregulated in ILC-deficient *Rag2*^−/−^*Il2rg*^−/−^ mice compared to WT and *Rag2*^−/−^ mice, suggesting that eotaxin expression, and subsequent eosinophil recruitment to the heart, may occur in an ILC-dependent way *in vivo*. In addition, eotaxin expression was spatially concentrated in the pericardium and interstitial space, which could explain the specific inflammation pattern of eosinophilic pericarditis induced by IL-33.

We also found that cardiac ILC2s produce IL-5, which plays an important role in developing IL-33-induced pericarditis and that blocking of IL-5 protected mice from the development of eosinophilic pericarditis. In response to IL-5, eosinophils are released into the circulation, which may be hindered by blocking IL-5. Several anti-IL-5 agents, including mepolizumab, reslizumab, and benralizumab, which block IL-5 signaling via IL-5 receptor and reduce blood eosinophils, have been developed, approved, and used to treat asthma in clinical practice ([@R17]). In addition, a phase II clinical trial ([NCT02130882](https://clinicaltrials.gov/ct2/show/NCT02130882)) is evaluating the safety and efficacy of benralizumap, an anti-IL-5 receptor biologic, in decreasing eosinophils in patients with hypereosinophilic syndrome. We found that anti-IL-5 treatment had a profound effect on reducing eosinophils infiltrating to the heart during pericarditis, suggesting that anti-IL-5/IL-5R agents could be used as a potential treatment for eosinophilic pericarditis.

IL-33-induced cardiac inflammation has a unique pattern affecting mostly pericardium and myopericardium; therefore, we explored whether eosinophils could migrate from a non-vascular source such as the mediastinal cavity, a neighboring serosal cavity. We identified that eosinophils are present in the mediastinal cavity of naive mice and that adoptively transferred eosinophils to the mediastinal cavity of IL-33-treated eosinophil-deficient mice are able to traffic to the heart. This suggests that the serous cavities may serve as a reservoir of cardiac-infiltrating eosinophils. Immune cells have been previously identified in serous cavities such as the peritoneum and pleural cavity ([@R23]; [@R60]; [@R70]; [@R71]; [@R12]). Macrophages residing in the peritoneal cavity are rapidly recruited to the injured liver through a non-vascular route and display tissue-reparative phenotypes ([@R70]). Macrophages found in mouse pericardial fluid played a reparative role after myocardial infarction ([@R12]). The pleural space is also shown to possess B1a B cells, which can migrate to the lung and produce protective IgM in response to bacterial infection ([@R71]). We found that eosinophils residing in the mediastinal cavity can migrate to the heart. There are pericardial pores between pericardial, pleural, and mediastinal cavities ([@R19]). Therefore, all of these cavities should be considered a possible source of cells infiltrating to the heart. This does not exclude the contribution of circulating eosinophils to the development of pericarditis; however, it is noteworthy that the mediastinal cavity can serve as an alternative reservoir of eosinophils, which may lead to rapid infiltration during inflammation in close proximity to the heart. IL-33 treatment also induces inflammation in lungs and esophagus, as we demonstrated here and shown before by others ([@R66]; [@R30]). After treating mice with IL-33, we found pericardial, subserosal, and peribronchial eosinophil infiltrates in the heart, esophagus, and lungs, respectively. IL-33-induced esophagitis has a subserosal inflammation pattern that is similar to IL-33-induced pericarditis, with the inflammation mostly confined to the subserosa rather than to the mucosa. Based on these observations, we speculate that the chest serosal cavities could also be a source of eosinophils for other organs located in the mediastinal cavity. This could be important in patients with hypereosinophilia, since we showed that hypereosinophilic mice have more eosinophils in their mediastinum than do WT mice. Our findings suggest that ILC2s may direct eosinophils to infiltrate organs, not only from the blood but also from the neighboring serosal cavity where these cells reside locally.

Serosal fluid in the pericardium contains immune cells and can become a source of infiltrating leukocytes under certain insults such as exposure following cardiac surgery and myocardial infarction ([@R6]; [@R26]). We found that ILCs were present at a higher frequency in the pericardial fluid of patients with pericarditis, whereas healthy controls and patients with other types of cardiac diseases such as cardiomyopathy showed a much lower frequency of ILCs in the pericardial fluid. The number of patients tested was limited; therefore, further clinical investigation will be needed. However, this result suggests that ILCs may also be involved in the pathogenesis of pericarditis in humans. It is unclear whether the increase in ILCs results from other underlying causes such as infection and whether ILCs directly induce human pericarditis, as shown in the IL-33-induced pericarditis mouse model.

Although many pericarditis case reports have been published, the etiology is still largely unknown. Contemporary treatments for pericarditis mostly aim to resolve symptoms by administrating anti-inflammatory agents such as nonsteroidal anti-inflammatory drugs (NSAIDs, especially indomethacine), colchicine, and corticosteroids ([@R28], [@R29]). A phase III clinical trial ([ClinicalTrials.gov](http://ClinicalTrials.gov): [NCT03737110](https://clinicaltrials.gov/ct2/show/NCT03737110)) is assessing the IL-1 blocker in patients with recurrent pericarditis. Another treatment option for severe cases is a pericardiocentesis or pericardiectomy to remove the inflamed pericardium. These symptomatic therapies, however, do not address a specific cause of pericarditis. One of the problems in developing new targeted therapies is a lack of classification on subtypes of pericarditis. There are several case reports of eosinophilic pericarditis in humans ([@R38]; [@R61]; [@R25]; [@R1]; [@R67]). In this study, using the IL-33-induced eosinophilic pericarditis mouse model, we identified cardiac ILC2s playing a critical role in the pathogenesis of eosinophilic pericarditis. We also showed limited human data that suggest an increased number of ILCs in the pericardial fluid of pericarditis patients. These findings augment our understanding of how ILC2s contribute to cardiac inflammation and provide insights into targeted therapy for eosinophilic pericarditis. In a setting where there is no specific way to target ILC2s, it may be helpful to alleviate eosinophilic pericarditis by blocking the IL-33-ST2-ILC2s axis.

Our findings suggest a pathogenic role for ILCs in cardiac inflammation. ILCs play a critical role in the development of pericarditis induced by IL-33, as their presence and activation are essential components to inducing pericarditis. Our study provides insights into the role of cardiac ILCs in inflammation that can be helpful to developing therapeutic targets for pericarditis.

STAR★METHODS {#S11}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S12}
---------------------------------------

This study did not generate new unique reagents. Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Daniela Čiháková (<cihakova@jhmi.edu>).

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S13}
--------------------------------------

### Human samples {#S14}

Human pericardial fluid samples were obtained from patients with pericarditis, ARVC, IHD or valve disease. Samples were collected while these patients underwent coronary artery bypass grafting, valve replacement surgery or pericardiocentesis at the Institute for Clinical and Experimental Medicine (IKEM) in Czech Republic. Informed consent was obtained from subjects and the study protocol was approved by the IKEM Ethics Committee (G-18-60). Control pericardial fluid specimens were obtained from rapid autopsy of patients who had no cardiovascular diseases at the Johns Hopkins University. Informed consent was obtained from subjects and the study protocol was approved by the Committee for the Protection of Human Subjects (IRB NA_00036610, PI: Jody Hooper). Sex of human sample donors is indicated below: Controls, 1 male and 2 females; ARVC, 1 male and 2 females; IHD, 11 males and 4 females; Valve disease, 2 males and 2 females; Pericarditis, 1 male and 1 female. Pericardial fluid cells were isolated by centrifugation, resuspended in fetal bovine serum (FBS) supplemented with 10% DMSO, and stored in a liquid nitrogen tank. Frozen samples were shipped on dry ice. Patients' information of all samples was processed with random non-linked code labeling in a database at the time of preservation. For each sample, a separate random non-linked code was assigned for the analysis process.

### Animals {#S15}

Wild-type BALB/cJ (JAX 651), *Rag2*^−/−^ (JAX 8448), *Rag2*^−/−^*γc*^−/−^ (JAX 14593), CD45.1/cByJ (JAX 6584), ΔdblGATA1 (JAX 5653) mice were obtained from the Jackson Laboratory (Bar Harbor, ME). ST2^−/−^, IL-13^−/−^ and IL-33^cit/+^ mice were kindly provided by Andrew N.J. McKenzie (Medical Research Council, Cambridge, UK). IL-33^cit/cit^ mice were used as IL-33^−/−^ mice. IL-5Tg mice were kindly provided by James Lee (Mayo Clinic, Scottsdale, AZ). Mice used were 6 to 12-week-old male mice on the BALB/c background unless otherwise mentioned in the figure legends. Mice were maintained at the Johns Hopkins University School of Medicine specific pathogen-free animal facility. Experiments were performed with age-matched mice in accordance with the guidelines set forth in the Guide for the Care and Use of Laboratory Animals. All methods and protocols were approved by the Animal Care and Use Committee of Johns Hopkins University.

### Isolation of primary adult mouse cardiac fibroblasts {#S16}

Hearts were isolated from 6-12-week-old WT BALB/c mice pretreated *i.p.* with PBS with 50U/ml Heparin. Hearts were cannulated through aorta and perfused for 3 min at 37°C with calcium-free perfusion buffer (7.03 g/L NaCl, 1.1 g/L KCl, 0.082 g/L KH~2~PO~4~, 0.085 g/L Na~2~HPO~4~, 0.144 g/L MgSO~4~, 2.38 g/L HEPES, 0.39 g/L NaHCO~3~, 1 g/L glucose, 3.74 g/L Taurine, 1 g/L 2,3-Butanedione monoxime; all Sigma-Aldrich) and for 8 min with the addition of Collagenase II (Worthington Biochemical Corporation) and Protease XIV (Sigma-Aldrich) and 0.03M CaCl2. The heart was cut into pieces and digested by gentle pipetting for 3 min or until large pieces are fully digested. After filtering through a 100 μm strainer and washing with DMEM (GIBCO), cardiac fibroblasts in cell suspensions were separated from cardiac myocytes that precipitated rapidly and spontaneously. Cardiac fibroblasts were cultured at 37°C in DMEM with 20% FBS (GE Healthcare Life Siences), Non-essential amino-acids (Sigma Aldrich), Penicillin-Streptomycin, 2 mM L-Glutamine, and 25 mM HEPES (all Quality Biological). Nonadherent cells were washed off after 1 h. Culture media was changed every day for 5 days until cardiac fibroblasts are confluent. Cardiac fibroblasts were passaged twice before co-culture.

METHOD DETAILS {#S17}
--------------

### Induction of experimental pericarditis {#S18}

Mice were injected with 1 μg of recombinant mouse IL-33 (BioLegend) in 100 μL PBS intraperitoneally on days 0, 2, 4, 6 and 8. On day 9 or 10, hearts were harvested for further analysis detailed below.

### Assessment of pericarditis severity {#S19}

Hearts were cut transversely, fixed in SafeFix (Thermo Fisher Scientific), embedded in paraffin, cut into 5 μm-thick sections and stained with H&E (Histoserv, MD). The severity of pericarditis was assessed by scoring infiltration of the area of pericardium around right ventricle (RV) on H&E-stained sections based on histopathology score from 0 to 4 using the following criteria for hematopoietic infiltrates: grade 0, no inflammation; grade 1, \< 20% of RV is involved and/or mild inflammation; grade 2, 20%--50% of RV is involved and/or intermediate inflammation; grade 3, 50%--80% of RV is involved and/or severe inflammation; grade 4, \>80% of RV is involved and/or severe inflammation with adjacent myocardial infiltrates. Scoring was performed by two blinded investigators and averaged.

### Light microscopy {#S20}

Images on H&E-stained and immunostained sections were acquired on the BX43 microscope (Olympus) with the DS-Fi3 camera (Nikon) using NIS-Elements D Software (v. 5.10.01, Nikon).

### Tissue clearing with immunolabeling and light sheet microscopy {#S21}

Hearts were perfused with PBS for 3 min followed by 4% paraformaldehyde in PBS for 3 min for fixation. After perfusion, hearts were removed from mice and the right ventricle was obtained and immersed in 4% paraformaldehyde in PBS for 2 h at 4°C to complete fixation. After washing with PBS, the sample was permeabilized, washed, penetrated, and blocked using Visikol HISTO reagents (Visikol) according to manufacturer's protocols. Primary and secondary antibody staining were performed using 10 μg/ml anti-mouse SiglecF (BD) and KLRG1 (ProSci) antibodies and 20 μg/ml anti-rat and anti-hamster IgG conjugated with fluorophores (Thermo Fisher Scientific), respectively, in Visikol HISTO antibody buffer (Visikol) according to manufacturer's protocols. After immunolabeling, tissue clearing process was conducted using Visikol HISTO-1 and −2 (Visikol) following manufacturer's instruction. Images of cleared tissue with immunolabeling were acquired using a light sheet microscope, Ultra Microscope II (LaVision Biotec). Processing of images was carried out with Imaris (Bitplane).

### Immunofluorescence staining and confocal microscopy {#S22}

Mouse heart was perfused with PBS for 3 min followed by 4% paraformaldehyde in PBS for 3 min for fixation. After perfusion, heart was removed from mice and immersed in 4% paraformaldehyde in PBS for 2 h at 4°C to complete fixation. After fixation, the heart was placed in 30% sucrose in PBS overnight or until tissue sinks at 4°C before embedding in OCT. Cryostat sectioning was performed to obtain heart sections in a 100 μm-thickness. Sections were washed in PBS, permeabilized in 0.5% Triton X-100 in PBS and blocked in 10% normal goat serum and 0.3% Triton X-100 in PBS. After blocking, sections were incubated with Rabbit anti-PDGFRα antibody (Abcam). Goat anti-Rabbit IgG conjugated with Alexa Fluor 555 (Thermo Fisher) was used as secondary antibody and DAPI was used for counterstaining. Images were acquired using Zeiss LSM 700 microscope (Zeiss) at 20X and 40X magnification with the ZEN Black software (Zeiss). ImageJ/Fiji was used to process images.

### Immunohistochemistry staining {#S23}

Paraffin-embedded hearts were cut into 4-μm-thick sections. After deparaffinization, heat-induced antigen retrieval and blocking, sections were stained with 5 μg/ml Polyclonal Goat Anti-Mouse CCL11 antibody (R&D Systems) and Anti-Goat HRP-DAB Cell & Tissue Staining Kit (R&D Systems) and counter stained with Hematoxylin.

### Echocardiography {#S24}

Conscious mice were held in a supine position and M-mode or Doppler echocardiography was performed using Vevo 2100 with a MS400 or MS550D transducer (FUJIFILM VisualSonics, Ontario, Canada). In M-mode, the heart was imaged in the parasternal short axis view to measure parameters such as left ventricular internal dimension (LVID) and ejection fraction (EF). To measure the Myocardial Performance Index (MPI), tissue Doppler imaging of the mitral annulus was obtained. Cardiac time intervals, isovolumetric contraction time (IVCT), isovolumetric relaxation time (IVRT) and ejection time (ET), were measured and MPI was calculated based on these parameters ([@R20]).

### High-dimensional mass cytometry (CyTOF) {#S25}

Frozen cells were thawed at 37°C and washed with PBS twice. Single cell suspensions were stained with Cell-ID Cisplatin (Fluidigm), blocked with Fc Receptor Binding Inhibitor (Thermo Fisher), and stained with heavy metal-conjugated antibodies (Fluidigm) for surface staining. Cells were fixed and permeabilized with FoxP3 Transcription Factor Staining Buffer Set (Thermo Fisher) followed by intracellular staining with metal-conjugated antibodies (Fluidigm). Cells were fixed in methanol-free formaldehyde (Thermo Fisher) and kept in Cell-ID Intercalator-Ir solution (Fluidigm). Stained cells were shipped on ice to the CyTOF Facility at the University of Pennsylvania and acquired on Helios (Fluidigm). CyTOF data were normalized in the CyTOF software (Fluidigm) and analyzed using Cytobank (Cytobank Inc).

### Flow cytometry and cell sorting {#S26}

Hearts were perfused with PBS through ventricles, cut into small pieces and digested in gentleMACS C Tubes (Miltenyi Biotec) with 3000U Collagenase II and 300U DNase I (Worthington Biochemical Corporation) in HBSS for 30 min at 37°C. To generate single cell suspensions, hearts were mechanically dissociated using GentleMACS dissociator (Miltenyi Biotec) following manufacturer's protocols. Cells in the mediastinal cavity were harvested by lavage with PBS. Blood was collected in PBS with 100U/ml Heparin and overlaid on Histopaque-1119 (Sigma Aldrich) to remove red blood cells. Remaining red blood cells were lysed using ACK buffer (Quality Biological). Cells from heart samples were strained through a 40 μm filter, and cells from other organs were strained through a 70 μm filter. For intracellular cytokine staining, cells were stimulated with 50 ng/ml PMA, 750 ng/ml Ionomycin (Sigma-Aldrich), GolgiStop and GolgiPlug (BD Biosciences) for 4 h at 37°C before staining. Single cell suspensions were stained with LIVE/DEAD Fixable Aqua (Thermo Fisher Scientific). FcγRII/III was blocked with anti-mouse CD16/CD32 (eBioscience), and markers of interest were stained with flourochrome-conjugated antibodies (BD, BioLegend and eBioscience). Lineage (Lin) used for identifying mouse ILC2s included CD3ε, TCRβ, CD19, B220, CD11b, CD11c, Gr-1, Ter119, FcεRIα and NKp46. To quantify absolute number of cells, viable cells were counted using CountBright Absolute Counting Beads (Thermo Fisher Scientific). Samples were acquired on BD LSR II or Fortessa (BD Biosciences) and data were analyzed using FlowJo V10 (Tree Star). For cardiac ILC2 sorting, after enzymatic and mechanical dissociation of hearts, single cell suspensions were obtained using Histopaque-1077 (Sigma-Aldrich) according to manufacturer's instructions. Collected mononuclear cells were stained and sorted on BD FACSAria II (BD Biosciences).

### Isolation and *in vitro* expansion of cardiac ILC2 {#S27}

Cardiac ILC2s were isolated using FACSAria II (BD Biosciences) from the hearts of IL-33-treated mice and cultured at 37°C in RPMI 1640 (GIBCO) with 10% FBS (GE Healthcare Life Sciences), 1% Penicillin-Streptomycin, 2 mM L-Glutamine, 10 mM HEPES, 1 mM Sodium Pyruvate (all Quality Biological), 0.1 mM Non-essential amino acids (Sigma Aldrich), 0.05 mM 2-Mercaptoethanol (GIBCO). Cytokines, IL-2, IL-7 and IL-33, at a concentration of 25 ng/ml were added in media to expand ILC2s *in vitro.*

### Cardiac injection of ILC2 {#S28}

CD45.2^+^ *Rag2*^−/−^*γc*^−/−^ mice were anesthetized with 3.5% isoflurane (Baxter) and tracheal intubation was performed immediately. While on intubation, mice were provided with oxygen with 2% isoflurane by mechanical ventilation system (Model 845, Harvard Apparatus). Pre-operational analgesics (0.05 mg/kg Buprenorphine, Reckitt Benckiser) and paralytics (1 mg/kg Succinylcholine, Henry Schein) were treated before operation. Thoracotomy was done to access the chest cavity and expose the ventricles of the heart. 5x10^5^ CD45.1^+^ cardiac ILC2s were injected into the myocardium on three ventricular locations using a 29G ½ insulin syringe (BD). Post-operational analgesics (0.05 mg/kg Buprenorphine) were administered during recovery.

### *In vitro* co-culture of cardiac fibroblasts and ILC2 {#S29}

ILC2s were FACS-sorted from the hearts of I L-33-treated mice and expanded *in vitro* as described above. 1x10^5^ ILC2s were placed on Transwell with 0.4 μm pore polyester membrane insert (Corning). Cardiac fibroblasts from second passage were co-cultured with ILC2s located on Transwell at 37° C in ILC2 culture media for 24 h. 25 ng/ml IL-2 and 25 ng/ml IL-7 were included in co-culture and 25 ng/ml IL-33 was added in certain conditions indicated. Cells and supernatants were harvested after co-culture and used for further analysis.

### *In vivo* IL-5 neutralization {#S30}

To block IL-5 *in vivo*, mice were treated *i.p.* with 300 μg of anti-IL-5 monoclonal antibody (Clone: TRFK5, BioXCell) or isotype antibody (Clone: HRPN, BioXCell) every three days starting from a day before pericarditis induction.

### Eosinophil isolation, labeling, and transfer to the mediastinal cavity or intravenously {#S31}

Blood from donor IL-5Tg mice was collected in PBS with 100U/ml Heparin and overlaid on Histopaque-1119 (Sigma Aldrich) to remove red blood cells. Anti-CD90.2 and anti-CD45R(B220) microbeads (Miltenyi Biotec) were used to deplete lymphocytes and enrich eosinophils. Eosinophil purity (78%--95%) was determined by flow cytometry. For labeling, cells were stained with either CellTrace™ Violet (CTV) or CellTrace™ Far Red (CTFR) according to manufacturer's instructions (Thermo Fisher). Recipient mice were anesthetized with 500 μL avertin or isoflurane and 1-8x10^6^ cells were injected to the mediastinal cavity or by retro-orbital injection using a 29G ½ insulin syringe (BD).

### Quantitative PCR {#S32}

RNA was extracted in TRIzol (Invitrogen) and cDNA was synthesized using iScript cDNA Synthesis Kit (Bio-Rad). Quantitative PCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems) and executed on MyiQ2 thermal cycler (Bio-Rad) using iQ5 optical system software (Bio-Rad). Acquired data were analyzed by the 2^−ΔΔCt^ method ([@R40]). Threshold cycles were normalized to the expression of *Gapdh* and then to controls. Primers for genes (*Ccl11*: 5′-GAATCACCAACAA CAGATGCAC-3′ and 5′-ATCCTGGACCCACTTCTTCTT-3′, *Ccl24*: 5′-TCTTAGGGCCCTTCTTGGTG-3′ and 5′- AATTCCAGAAAAC CGAGTGG-3′, *Il5*: 5′-CTCTGTTGACAAGCAATGAGACG-3′ and 5′-TCTTCAGTATGTCTAGCCCCTG-3′, *Il13*: 5′-CCTGGCTCTTG CTTGCCTT-3′ and 5′-GGTCTTGTGTGATGTTGCTCA-3′, *Gapdh*: 5′-TTGATGGCAACAATCTCCAC-3′ and 5′-CGTCCCGTAGACA AAATGGT-3′) were commercially synthesized (Integrated DNA Technologies).

### ELISA {#S33}

Supernatants from cardiac fibroblasts co-culture with ILC2s or sera from mice were stored at −80°C prior to ELISA. Eotaxin-1 was determined by quantitative sandwich ELISA using Mouse CCL11/Eotaxin Quantikine ELISA Kit (R&D Systems) according to manufacturer's protocols. For anti-myosin IgM ELISA, plates were coated with 0.5 μg/well myosin heavy chain α peptide MyHCα~614-62g~ (Ac-SLKLMATLFSTYASAD; Genscript) and Alkaline Phosphatase AffiniPure goat anti-mouse IgM, μ chain specific (Jackson ImmunoResearch) at a 1:4000 dilution was used to detect anti-myosin IgM in sera.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S34}
---------------------------------------

### Statistical analysis {#S35}

Two group comparisons were performed using Student's t test for normally distributed data. Multiple group comparisons were performed using one-way ANOVA followed by Tukey's post hoc test. Mann-Whitney U test or Kruskal-Wallis H test for two groups or multiple groups, respectively, was used for nonparametric data. Pearson correlation coefficient, r, was calculated using correlation analysis in Prism 6 (GraphPad Software Inc.). Statistical analysis was conducted in Prism 6. Statistically significant comparisons were represented by asterisks: \*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001. Statistical analysis details are also described in the figure legends.

DATA AND CODE AVAILABILITY {#S36}
--------------------------

This study did not generate datasets.
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![ILC2s Increases in the Heart, and Cardiac Function Is Changed following IL-33 Treatment\
(A) Representative images of H&E-stained heart sections of the median mice treated with either PBS or IL-33. Areas marked by rectangles are shown as enlarged images in the right panels. Bars: 1 mm (left) and 100 μm (right).\
(B) Representative M-mode pictures of animals treated with PBS or IL-33. Bars: blue, 1 mm; white, 0.1 s. LVESD, left ventricular end-systolic diameter; LVEDD, left ventricular end-diastolic diameter.\
(C and D) Ejection fraction (EF) (C) and fractional shortening (FS) (D) of WT mice treated with PBS or IL-33.\
(E and F) Isovolumetric relaxation time (IVRT) (E) and myocardial performance indexes (MPI) (F) of the heart from mice treated with PBS or IL-33 were assessed by Doppler echocardiography on day 9 post-PBS or IL-33 treatment.\
(G) Total number of heart-infiltrating CD45^+^ leukocytes was determined by flow cytometry.\
(H--J) Number of (H) ILC2s, (I) eosinophils, and (J) mast cells in the hearts. Absolute cell counts per heart were calculated using counting beads for flow cytometry (see [Method Details](#S17){ref-type="sec"}).\
(K) Image of the right ventricle of the heart from *Rag2*^−/−^ mice treated with IL-33. Green and red dots represent KLRG1^+^ ILC2s (white arrows) and SiglecF^+^ eosinophils (red arrowheads), respectively. Scale bar: 500 μm. Data are representative of three independent experiments.\
Data are displayed as the means. Unpaired t test (C--J) was used for statistical analysis. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.\
See also [Figures S1](#SD1){ref-type="supplementary-material"} and [S2](#SD1){ref-type="supplementary-material"} and [Video S1](#SD3){ref-type="supplementary-material"}.](nihms-1595651-f0002){#F1}

![IL-33-ST2 Axis Is Critical for the Development of Pericarditis\
(A) Representative images of H&E-stained heart sections of WT and ST2^−/−^ mice. Bars: 100 μm.\
(B) Severity of pericarditis was scored on H&E-stained heart sections.\
(C) Number of heart-infiltrating CD45^+^ leukocytes was determined by flow cytometry.\
(D) Representative flow cytometry plots of CD45^+^Lin^−^ cells. Gates show the frequency of CD90^+^KLRG1^+^ ILCs in the heart of WT and ST2^−/−^ mice.\
(E and F) Number of (E) Lin^−^CD90^+^KLRG1^+^ ILCs and (F) eosinophils in the hearts.\
(G) Mean fluorescence intensity (MFI) of IL-33 expression in cardiac viable cells.\
(H) Number of IL-33-expressing cells in the hearts.\
(I) Mean frequency of different IL-33-expressing populations. The mean was quantified using values in a PBS-treated group (n = 4) and an IL-33-treated group (n = 5). Areas of the pie charts are proportional to total IL-33^+^ cells in the heart.\
(J) Total number of IL-33^+^Sca1^+^ cardiac fibroblasts.\
(K) PDGFRα expression by Sca1^+^ cardiac fibroblasts.\
(L) Immunofluorescence imaging shows IL-33-expressing PDGFRα^+^ cardiac fibroblasts near the pericardium (white arrows) and in the pericardium (yellow arrows). Blue, green, and red color represent DAPI, IL-33, and PDGFRα, respectively. Bars: 50 μm.\
Data are representative of two independent experiments and displayed as the mean. Mann-Whitney *U* test (B) or unpaired t test (C, E--H, and J) was used for statistical analysis. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.\
See also [Figure S3](#SD1){ref-type="supplementary-material"}.](nihms-1595651-f0003){#F2}

![ILCs Are Required for the Development of Pericarditis, and ILC2s Are Sufficient to Induce Eosinophilic Infiltration to the Heart\
(A) Representative images of H&E-stained heart sections of WT (left), *Rag2*^−/−^ (center), and *Rag2*^−/−^ *Il2rg*^−/−^ (right) mice. Bars: 100 μm.\
(B) Severity of pericarditis was scored on H&E-stained heart sections.\
(C) Total number of heart-infiltrating CD45^+^ leukocytes was determined by flow cytometry.\
(D and E) Number of (D) ILC2s and (E) eosinophils in the hearts.\
(F) Representative flow cytometry plots of ILC2s found in the hearts of naive *Rag2*^−/−^*Il2rg*^−/−^ mice and *Rag2*^−/−^*Il2rg*^−/−^ mice injected with media or ILC2s followed by IL-33 treatment.\
(G) Number of heart-infiltrating CD45.2^+^ leukocytes.\
(H) Representative flow cytometry plots of CD45.2^+^ cells. Gates show the frequency of CD11b^+^SiglecF^+^ eosinophils in the hearts of naive *Rag2*^−/−^*Il2rg*^−/−^ mice and *Rag2*^−/−^*Il2rg*^−/−^ mice injected with media or ILC2s followed by IL-33 treatment.\
(I) Number of eosinophils in the hearts.\
Both male and female mice were used in each group in (B). Data are representative of two independent experiments and displayed as the mean. Kruskal-Wallis H test (B) or one-way ANOVA followed by Tukey's post hoc test (C--E, G, and I) was used for statistical analysis. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.\
See also [Figure S4](#SD1){ref-type="supplementary-material"}.](nihms-1595651-f0004){#F3}

![Cardiac Fibroblasts Increase CCL11/Eotaxin-1 Expression and Production When Co-cultured with IL-33-Stimulated ILC2s, and the Expression of Eotaxins and Type 2 Cytokines Is Dependent on ILCs\
(A) Expression of the *Ccl11* gene encoding eotaxin-1 in heart homogenates was analyzed by qPCR.\
(B) Schematic description of cardiac fibroblasts co-culture with ILC2s separated by 0.4-μm transwell.\
(C) Expression of *Ccl11* in cardiac fibroblasts was analyzed by qPCR.\
(D) Eotaxin-1 concentrations in cell culture supernatants were measured by ELISA. IL-2 and IL-7 were included in culture media and IL-33 was added where indicated (C and D).\
(E--H) Expression of genes in heart homogenates from WT, *Rag2*^−/−^, and *Rag2*^−/−^*Il2rg*^−/−^ mice treated with IL-33 was analyzed by qPCR. *Ccl11* (E), *Ccl24* (F), *Il5* (G), and *Il13* (H).\
(I) Immunohistochemistry staining for CCL11 of heart sections from WT mice treated with PBS or IL-33. Bars: 50 μm.\
Data are representative of two independent experiments and displayed as the mean with SD. Unpaired t test (A) or one-way ANOVA followed by Tukey's post hoc test (C--H) was used for statistical analysis. \*p \< 0.05; \*\*p \< 0.01; \*\*\*p \< 0.001.\
See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1595651-f0005){#F4}

![IL-5 Produced by ILC2s Play a Role during the Development of Pericarditis\
(A) Representative flow cytometry plot of intracellular staining of IL-5 and IL-13 in cardiac ILC2s from IL-33-treated mice.\
(B) Frequency of ILC2s producing IL-5 and/or IL-13 in the hearts of IL-33-treated mice.\
(C) Representative images of H&E-stained heart sections of IL-33-treated mice with isotype or anti-IL-5 administration. Bars: 100 μm.\
(D) Total number of heart-infiltrating CD45^+^ leukocytes.\
(E and F) Number of (E) eosinophils and (F) ILC2s in the hearts of IL-33-treated WT mice with isotype or anti-IL-5 administration.\
(G) Representative images of H&E-stained heart sections of IL-33-treated WT and IL-13^−/−^ mice. Bars: 100 μm.\
(H) Total number of heart-infiltrating CD45^+^ leukocytes.\
(I and J) Number of (I) eosinophils and (J) ILC2s in the hearts of IL-33-treated WT and IL-13^−/−^ mice. Data are representative of two independent experiments and displayed as the mean. One-way ANOVA followed by Tukey's post hoc test (B) or unpaired t test (D--F and H--J) was used for statistical analysis. \*\*p \< 0.01; \*\*\*p \< 0.001.](nihms-1595651-f0006){#F5}

![Eosinophils Reside in the Mediastinal Cavity from Which These Cells Can Traffic to the Heart\
(A) Representative flow cytometry plot of CD45^+^CD11b^+^ cells. Gates show CD11b^+^SiglecF^+^ eosinophils and CD11b^+^Ly6G^+^ neutrophils in the heart, mediastinal cavity, and blood of WT naive mice.\
(B) Frequency of eosinophils in the heart, mediastinal cavity, and blood of WT naive mice.\
(C) Representative flow cytometry plot of CD45^+^CD11b^+^ cells. Gates show CD11b^+^SiglecF^+^ eosinophils and CD11b^+^Ly6G^+^ neutrophils in the heart, mediastinal cavity, and blood of IL-5Tg naive mice.\
(D) Frequency of eosinophils in the heart, mediastinal cavity, and blood of IL-5Tg naive mice.\
(E) Schematic description of eosinophil transfer to eosinophil-deficient ΔdblGATA1 mice.\
(F) Flow cytometry plots of CTV- or CTFR-labeled eosinophils.\
(G) Flow cytometry plot of CD45^+^ cells in the heart. Gate shows CD11b^+^SiglecF^+^ eosinophils found in the heart of ΔdblGATA1 mice treated with IL-33 after eosinophil transfer in the mediastinal cavity and i.v.\
(H) CTV- or CTFR-labeled CD11b^+^SiglecF^+^ eosinophils found in the heart of ΔdblGATA1 mice treated with IL-33 after eosinophil transfer.\
(I) Frequency of CTV- or CTFR-labeled eosinophils found in the heart of ΔdblGATA1 mice treated with IL-33.\
Concatenated samples (n = 7) are shown in (G) and (H). Both male and female mice were used in (G)--(I). Data are representative of two independent experiments and displayed as the mean (B and D) or the mean with SD (I). One-way ANOVA followed by Tukey's post hoc test (B and D) or unpaired t test (I) was used for statistical analysis. \*\*p \< 0.01.\
See also [Figure S6](#SD1){ref-type="supplementary-material"}.](nihms-1595651-f0007){#F6}

![ILCs Are Increased in the Pericardial Fluid from Patients with Pericarditis\
(A) Gating strategy of ILCs in human pericardial fluid samples by CyTOF. L/D, live/dead.\
(B) Representative CyTOF plots showing ILCs in the pericardial fluid from controls and patients with cardiac diseases. ARVC, arrhythmogenic right ventricular cardiomyopathy; IHD, ischemic heart disease.\
(C) Frequency of ILCs in the pericardial fluid.\
(D) Flow cytometry plots showing Lin^−^CD127^+^ ILCs in the pericardial fluid from controls and patients with pericarditis. Plots show a CD45^+^CD11b^−^CD3^−^CD19^−^CD56^−^ population. Lin included CD1a, CD11c, CD14, CD34, CD123, CD303a(BDCA2), TCRαβ, and FcεRIα.\
Concatenated samples (control, n = 3; pericarditis, n = 2) are shown in (D). One-way ANOVA followed by Tukey's post hoc test (C) was used for statistical analysis. \*\*\*p \< 0.001.](nihms-1595651-f0008){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                                SOURCE                                                                     IDENTIFIER
  ---------------------------------------------------------------------------------- -------------------------------------------------------------------------- ----------------------------------------
  Antibodies                                                                                                                                                    
  [Table S1](#SD2){ref-type="supplementary-material"}                                N/A                                                                        N/A
  Biological Samples                                                                                                                                            
  Pericardial fluid samples                                                          Johns Hopkins University School of Medicine                                <https://www.hopkinsmedicine.org/som/>
  Pericardial fluid samples                                                          Institute for Clinical and Experimental Medicine, Prague, Czech Republic   <https://www.ikem.cz/en/>
  Chemicals, Peptides, and Recombinant Proteins                                                                                                                 
  Recombinant Mouse IL-33 (carrier-free)                                             BioLegend                                                                  Cat\#580508
  Collagenase, Type 2                                                                Worthington                                                                Cat\#LS004177
  Deoxyribonuclease I                                                                Worthington                                                                Cat\#LS002139
  Protease, Type XIV: Bacterial, From *Streptomyces griseus*                         Sigma                                                                      Cat\#P5147-5G
  ACK Lysing Buffer                                                                  Quality Biological                                                         Cat\#118-156-721
  Bovine Serum Albumin                                                               Sigma                                                                      Cat\#A3608-100G
  0.5M EDTA, pH8.0                                                                   Corning                                                                    Cat\#46-034-CI
  PMA                                                                                Sigma                                                                      Cat\#P1585
  Ionomycin                                                                          Sigma                                                                      Cat\#I9657
  BD GolgiPlug                                                                       BD Biosciences                                                             Cat\#555029
  BD GolgiStop                                                                       BD Biosciences                                                             Cat\#554724
  LIVE/DEAD Fixable Aqua Dead Cell Stain Kit                                         Thermo Fisher                                                              Cat\#L34966
  BV711 Streptavidin                                                                 BioLegend                                                                  Cat\#405241
  Streptavidin Alexa Fluor 350 Conjugate                                             Thermo Fisher                                                              Cat\#S11249
  BD CytoFix Fixation Buffer                                                         BD Biosciences                                                             Cat\#554655
  Fixation/Permeabilization Solution Set                                             BD Biosciences                                                             Cat\#554714
  eBioscience Foxp3/Transcription Factor Staining Buffer Set                         Thermo Fisher                                                              Cat\#00-5523-00
  CountBright Absolute Counting Beads                                                Thermo Fisher                                                              Cat\#C36950
  SafeFix II All-Purpose Fixative                                                    Fisher Scientific                                                          Cat\#23-042600
  DMEM                                                                               GIBCO                                                                      Cat\#11995-065
  RPMI 1640                                                                          GIBCO                                                                      Cat\#11875-093
  Heat Inactivated Fetal Bovine Serum                                                Thermo Fisher                                                              Cat\#10082147
  L-Glutamine                                                                        Corning                                                                    Cat\#25-005-CI
  Penicillin-Streptomycin                                                            Sigma                                                                      Cat\#P4333
  Antibiotic-Antimycotic solution (100x)                                             Corning                                                                    Cat\#30-004-CI
  Sodium Pyruvate                                                                    Sigma                                                                      Cat\#S8636
  1M HEPES Buffer pH7.3                                                              Quality Biological                                                         Cat\#118-089-721
  MEM Non-essential Amino Acid solution (100x)                                       Sigma                                                                      Cat\#M7145-100ML
  2-Mercaptoethanol                                                                  GIBCO                                                                      Cat\#21985-023
  Recombinant Mouse IL-2 (carrier-free)                                              BioLegend                                                                  Cat\#575404
  Recombinant Mouse IL-7 (carrier-free)                                              BioLegend                                                                  Cat\#577802
  Heparin sodium salt from porcine intestinal mucosa                                 Sigma                                                                      Cat\#H3393
  Trypsin 2.5%                                                                       Quality Biological                                                         Cat\#118-086-721
  Histopaque-1119                                                                    Sigma                                                                      Cat\#11191-100ML
  Histopaque-1077                                                                    Sigma                                                                      Cat\#10771-100ML
  CD90.2 MicroBeads, mouse                                                           Miltenyi Biotec                                                            Cat\#130-049-101
  CD45R (B220) MicroBeads, mouse                                                     Miltenyi Biotec                                                            Cat\#130-049-501
  TRIzol Reagent                                                                     Thermo Fisher                                                              Cat\#15596026
  iScript cDNA Synthesis Kit                                                         Bio-Rad                                                                    Cat\#1708891
  Power SYBR Green PCR Master Mix                                                    Thermo Fisher                                                              Cat\#4367659
  Normal Goat Serum Blocking Solution                                                Vector Laboratories                                                        Cat\#S-1000-20
  Prolong Glass Antifade Mountant                                                    Thermo Fisher                                                              Cat\#P36980
  Visikol HISTO Starter Kit                                                          VISIKOL                                                                    Cat\#HSK-1
  Forane Liquid for inhalation 100ml                                                 Baxter                                                                     Cat\#1001936040
  Buprenorphine(1mg/ml)                                                              ZooPharm                                                                   Cat\#BZ8069317
  Succinylcholine (20mg/ml)                                                          Hospira, Inc.                                                              Cat\#00409662902
  CellTrace Violet Cell Proliferation Kit                                            Thermo Fisher                                                              Cat\#C34557
  CellTrace Far Red Cell Proliferation Kit                                           Thermo Fisher                                                              Cat\#C34564
  MyHCα~614-629~ (Ac-SLKLMATLFSTYASAD)                                               GenScript                                                                  N/A
  Trilogy                                                                            Cell Marque                                                                Cat\#920P-04
  TBS with Tween (TBST), 20X Solution                                                Thermo Fisher                                                              Cat\#J75500-K2
  Dual Endogenous Enzyme Block                                                       Dako                                                                       Cat\#S2003
  Antibody Dilution Buffer                                                           Ventana                                                                    Cat\#ADB250
  Richard-Allan Scientific Signature Series Hematoxylin 1                            Thermo Fisher                                                              Cat\#7221
  Richard-Allan Scientific Signature Series Clear-Rite 3                             Thermo Fisher                                                              Cat\#6901
  Shandon Bluing Reagent                                                             Thermo Fisher                                                              Cat\#6769001
  Optic Mount I Toluene                                                              Mercedes Scientific                                                        Cat\#MER7722
  Maxpar PBS                                                                         Fluidigm                                                                   Cat\#201058
  Cell-ID Intercalator-Ir                                                            Fluidigm                                                                   Cat\#201192B
  Cell-ID Cisplatin                                                                  Fluidigm                                                                   Cat\#201064
  Maxpar Cell Staining Buffer                                                        Fluidigm                                                                   Cat\#201068
  Maxpar Fix and Perm Buffer                                                         Fluidigm                                                                   Cat\#201067
  16% Formaldehyde (w/v), Methanol-free                                              Thermo Fisher                                                              Cat\#28906
  Critical Commercial Assays                                                                                                                                    
  Mouse CCL11/Eotaxin-1 Quantikine ELISA Kit                                         R&D Systems                                                                Cat\#MME00
  Anti-Goat HRP-DAB Cell & Tissue Staining Kit                                       R&D Systems                                                                Cat\#CTS008
  Experimental Models: Organisms/Strains                                                                                                                        
  Mouse: WT: BALB/cJ                                                                 The Jackson Laboratory                                                     Cat\#000651
  Mouse: CD45.1^+^: CByJ.SJL(B6)-*Ptprc*^*a*^/J                                      The Jackson Laboratory                                                     Cat\#006584
  Mouse: *Rag2*^−/−^: C.B6(Cg)-*Rag2*^*tm1.1Cgn*^/J                                  The Jackson Laboratory                                                     Cat\#008448
  Mouse: *Rag2*^−/−^*Il2rg*^−/−^: C;129S4-*Rag2*^*tm1.1Flv*^ *Il2rg*^*tm1.1Flv*^/J   The Jackson Laboratory                                                     Cat\#014593
  Mouse: ΔdblGATA1: C.129S1(B6)-*Gata1*^*tm6Sho*^/J                                  The Jackson Laboratory                                                     Cat\#005653
  Mouse: ST2^−/−^ (BALB/c)                                                           [@R65] (Dr. McKenzie)                                                      N/A
  Mouse: IL-13^−/−^ (BALB/c)                                                         [@R43] (Dr. McKenzie)                                                      N/A
  Mouse: IL-33^cit/+^ (BALB/c)                                                       [@R72] (Dr. McKenzie)                                                      N/A
  Mouse: IL-33^−/−^: IL-33^cit/cit^ (BALB/c)                                         This paper                                                                 N/A
  Mouse: IL-5Tg (BALB/c)                                                             [@R36] (Dr. Lee)                                                           N/A
  Oligonucleotides                                                                                                                                              
  *Ccl11* forward primer: 5′-GAATCACC AACAACAGATGCAC-3′                              This paper                                                                 N/A
  *Ccl11* reverse primer: 5′-ATCCTGGAC CCACTTCTTCTT-3'                               This paper                                                                 N/A
  *Ccl24* forward primer: 5′-TCTTAGG GCCCTTCTTGGTG-3'                                This paper                                                                 N/A
  *Ccl24* reverse primer: 5′-AATTCCAG AAAACCGAGTGG-3′                                This paper                                                                 N/A
  *Il5* forward primer: 5′-CTCTGTTG ACAAGCAATGAGACG-3′                               This paper                                                                 N/A
  *Il5* reverse primer: 5′-TCTTCAGT ATGTCTAGCCCCTG-3′                                This paper                                                                 N/A
  *Il13* forward primer: 5′-CCTGGCTCTTGCTTGCCTT-3′                                   This paper                                                                 N/A
  *Il13* reverse primer: 5′-GGTCTTGT GTGATGTTGCTCA-3′                                This paper                                                                 N/A
  *Gapdh* forward primer: 5′-TTGATGG CAACAATCTCCAC-3′                                This paper                                                                 N/A
  *Gapdh* reverse primer: 5′-CGTCCC GTAGACAAAATGGT-3′                                This paper                                                                 N/A
  Software and Algorithms                                                                                                                                       
  FlowJo                                                                             FlowJo                                                                     RRID: SCR_008520
  PRISM                                                                              GraphPad                                                                   RRID: SCR_002798
  ImageJ                                                                             [@R58]                                                                     <https://imagej.nih.gov/ij/>
  Imaris                                                                             BitPlane                                                                   RRID: SCR_007370
  Cytobank                                                                           Cytobank                                                                   RRID: SCR_014043

###### Highlights

-   ILCs are required for the development of IL-33-induced eosinophilic pericarditis

-   ILC2s facilitate eotaxin expression in cardiac fibroblasts

-   Eosinophils in the mediastinum can migrate to the heart during pericarditis

-   ILCs are more frequently present in the pericardial fluid of pericarditis patients
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